CANC

Tema Oncology ETF

42.55

Aug 13 • 3:58 PM ET -0.52 (-1.22%)

42.71

Aftermarket • 7:34 PM ET +0.16 (0.38%)

Financial Exchange Traded Fund USA NASD

Category	Global or ExUS Equities - Industry Sector
Sponsor	Tema
Fund Family
Index	-
Index Weighting
Active/Passive
Dividend TTM	0.02 (0.05%)
Dividend Ex-Date	Dec 10, 2025
Dividend Gr. 3/5Y	- -
Expense	0.75%
Inverse/Leveraged
IPO	Aug 16, 2023

Asset Type	Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short	No / Yes

Tags	Global
Tags	equity
Tags	healthcare
Tags	-
Tags	-
Tags	-
Tags	-
Sector/Theme
Region
SMA20	2.44%
SMA50	5.92%
SMA200	14.89%

Return% 1Y	69.94%
Return% 3Y	-
Return% 5Y	-
Return% 10Y
Return% SI
Flows% 1M	1.19%
Flows% 3M	3.08%
Flows% YTD	34.91%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades

Total Holdings	59
AUM	206.77M
NAV/sh
52W High	43.38 -1.92%
52W Low	25.93 64.12%
Volatility	1.72% 2.19%
ATR (14)	0.90
RSI (14)	60.26
Beta	0.71
Rel Volume	0.61
Avg Volume	31.75K
Volume	19,214

Perf Week	1.52%
Perf Month	4.02%
Perf Quarter	11.63%
Perf Half Y	16.11%
Perf YTD	22.54%
Perf Year	61.29%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Prev Close	43.07
Price	42.55
Change %	-1.22%

Jan-09-26 10:00AM	Here's Why Biotech ETFs Are Rallying Hard (Zacks)
Dec-02-25 06:00AM	Temas Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance (Business Wire)
Nov-26-25 10:00AM	Be Thankful to These ETFs This Year (Zacks)
Nov-21-25 08:00AM	Inside the Recent Strength in Biotech ETFs (Zacks)
Oct-20-25 06:00AM	Biotech ETFs Bounce Back in 2025: Here's Why (Zacks)

Tema Oncology ETF seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

open in yahoo | open in marketwatch | open in google

CANC

Tema Oncology ETF

Upgrade your Finviz experience